|Videos|December 9, 2021
Recent Data Surrounding the Appropriate Candidates for Long-Acting Cabotegravir for HIV Prevention
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Advertisement
Pharmacy Times spoke with Dr. Elizabeth Sherman, PharmD, about her session at the ASHP Midyear 2021 conference, titled "Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection”.
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Low-Dose Cannabinoids Show Potential to Restore Serotonin Levels and Reduce Inflammation in HIV, Study Finds
2
FDA Approves New Dosing Strength of Xolair Biosimilar, Omlyclo
3
FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure
4
Pharmacists Can Advance Lung Cancer Screening Awareness in High-Risk Patients
5
